Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. From Wikipedia
Robust double-digit profit growth spurred a reassessment of a U.S. primary listing to strengthen its presence in the world’s largest biopharmaceutical market.
